PMID- 37715592
OWN - NLM
STAT- MEDLINE
DCOM- 20240403
LR  - 20240403
IS  - 2042-6984 (Electronic)
IS  - 2042-6976 (Linking)
VI  - 14
IP  - 4
DP  - 2024 Apr
TI  - Combination of omalizumab with allergen immunotherapy versus immunotherapy alone 
      for allergic diseases: A meta-analysis of randomized controlled trials.
PG  - 794-806
LID - 10.1002/alr.23268 [doi]
AB  - BACKGROUND: Allergen immunotherapy (AIT)-associated adverse events (AEs) limit 
      its usage in the management of allergic diseases. The monoclonal anti-IgE 
      antibody (omalizumab) and AIT have complementary actions. However, no consensus 
      has been reached on whether their combination could exert superior efficacy and 
      safety. OBJECTIVE: To evaluate whether the combination of AIT with omalizumab is 
      superior to AIT alone in treating allergic diseases. METHODS: The MEDLINE/PubMed, 
      Embase, Scopus and Cochrane Library databases were searched to identify 
      randomized control trials (RCTs) reporting the outcomes of omalizumab combined 
      with AIT (omalizumab + AIT) versus AIT alone. A random-effect model was 
      established to estimate outcomes with a 95% confidence interval (CI). RESULTS: A 
      total of 11 eligible RCTs (involving 901 patients) were screened out for the 
      meta-analysis. According to a pooled analysis, omalizumab + AIT significantly 
      increased the number of patients achieving the target maintenance dose (TMD) and 
      sustained unresponsiveness (SU) to allergens (odds ratio [OR] = 2.43; 95% CI: 
      1.33-4.44; p = 0.004; I(2) = 35%, and OR = 6.77; 95% CI: 2.10-21.80; p = 0.001; 
      I(2) = 36%, respectively). Similarly, individuals receiving the combination 
      therapy reported significantly fewer episodes of severe systemic AEs than AIT 
      alone (OR = 0.32; 95% CI: 0.18-0.59; p = 0.0003; I(2) = 0%). Meanwhile, the 
      improvements in symptom severity score (mean difference [MD] = -0.26), rescue 
      medication daily means score (MD = -0.14), and number of patients consuming 
      epinephrine in AIT (OR = 0.20) were all more evident than those in AIT alone. 
      CONCLUSION: Omalizumab + AIT can significantly enhance the efficacy and safety of 
      AIT by increasing TMD and SU to allergens, while decreasing severe systemic AEs.
CI  - (c) 2023 ARS-AAOA, LLC.
FAU - Zhang, Ying-Ying
AU  - Zhang YY
AUID- ORCID: 0009-0002-3651-9827
AD  - Department of Otorhinolaryngology & Clinical Allergy Center, The First Affiliated 
      Hospital, Nanjing Medical University, Nanjing, China.
FAU - Zhang, Min
AU  - Zhang M
AUID- ORCID: 0000-0001-5357-6773
AD  - Department of Otorhinolaryngology & Clinical Allergy Center, The First Affiliated 
      Hospital, Nanjing Medical University, Nanjing, China.
FAU - Zhang, Jia-Qi
AU  - Zhang JQ
AD  - Department of Otorhinolaryngology & Clinical Allergy Center, The First Affiliated 
      Hospital, Nanjing Medical University, Nanjing, China.
FAU - Li, Qiu-Qi
AU  - Li QQ
AD  - Department of Otorhinolaryngology & Clinical Allergy Center, The First Affiliated 
      Hospital, Nanjing Medical University, Nanjing, China.
FAU - Lu, Mei-Ping
AU  - Lu MP
AUID- ORCID: 0000-0001-8097-614X
AD  - Department of Otorhinolaryngology & Clinical Allergy Center, The First Affiliated 
      Hospital, Nanjing Medical University, Nanjing, China.
FAU - Cheng, Lei
AU  - Cheng L
AUID- ORCID: 0000-0001-6541-7702
AD  - Department of Otorhinolaryngology & Clinical Allergy Center, The First Affiliated 
      Hospital, Nanjing Medical University, Nanjing, China.
AD  - International Centre for Allergy Research, Nanjing Medical University, Nanjing, 
      China.
LA  - eng
GR  - JSDW202203/Jiangsu Province Capability Improvement Project through Science, 
      Technology and Education/
PT  - Journal Article
PT  - Meta-Analysis
DEP - 20230916
PL  - United States
TA  - Int Forum Allergy Rhinol
JT  - International forum of allergy & rhinology
JID - 101550261
RN  - 2P471X1Z11 (Omalizumab)
RN  - 0 (Allergens)
SB  - IM
MH  - Humans
MH  - *Omalizumab/therapeutic use
MH  - Randomized Controlled Trials as Topic
MH  - Desensitization, Immunologic/adverse effects
MH  - Allergens
MH  - *Hypersensitivity/etiology
OTO - NOTNLM
OT  - Allergen immunotherapy
OT  - allergic rhinitis
OT  - anti-IgE
OT  - asthma
OT  - food allergy
OT  - omalizumab
EDAT- 2023/09/16 10:42
MHDA- 2024/04/03 06:44
CRDT- 2023/09/16 05:27
PHST- 2023/08/22 00:00 [revised]
PHST- 2023/06/17 00:00 [received]
PHST- 2023/08/29 00:00 [accepted]
PHST- 2024/04/03 06:44 [medline]
PHST- 2023/09/16 10:42 [pubmed]
PHST- 2023/09/16 05:27 [entrez]
AID - 10.1002/alr.23268 [doi]
PST - ppublish
SO  - Int Forum Allergy Rhinol. 2024 Apr;14(4):794-806. doi: 10.1002/alr.23268. Epub 
      2023 Sep 16.